What is it about?

The issue of dialyzable and non-dialyzable beta-blockers for patients undergoing hemodialysis is gradually receiving attention. It is currently unknown whether the use of different types of beta-blockers has an impact on the prognosis of patients undergoing hemodialysis.

Featured Image

Why is it important?

We searched the database and identified relevant literature on the use of beta-blockers in hemodialysis patients. The prognosis was analyzed including major adverse cardiac events (MACE), acute myocardial infarction (AMI), and heart failure (HF).


I hope this article can provide more comprehensive evidence and confidence for clinical physicians regarding the use of beta-blockers in hemodialysis patients. I also expect that there will be more research on beta-blockers in hemodialysis patients in the future, providing more robust results.

Jui-Yi Chen
Chi-Mei Medical Center

Read the Original

This page is a summary of: Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis, PLoS ONE, December 2022, PLOS,
DOI: 10.1371/journal.pone.0279680.
You can read the full text:

Open access logo


The following have contributed to this page